Epalrestat-d5

目录号: GC47298纯度: >99.00%
A neuropeptide with diverse biological activities

Epalrestat-d5
Cas No.: N/A
规格价格库存数量操作
500 μg¥1,247.00现货
1
1 mg¥2,341.00现货
1

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

Epalrestat-d5 is intended for use as an internal standard for the quantification of epalrestat by GC- or LC-MS. Epalrestat is an inhibitor of aldose reductase (IC50s = 0.01 and 0.26 µM for rat lens and human placenta aldose reductase, respectively).1 It inhibits glucose-induced sorbitol accumulation in isolated rat lens, rat sciatic nerve, and human erythrocytes (IC50s = 1.5, 5, and 1.5 µM, respectively). It decreases high glucose-induced proliferation of vascular smooth muscle cells when used at a concentration of 10 nM and prevents high glucose-induced intracellular NADH/NAD+ increases and membrane-bound PKC activation at 100 nM.2,3 Epalrestat (20 and 40 mg/kg) improves motor nerve conduction velocity and decreases sorbitol content in the sciatic nerve and erythrocytes in a rat model of streptozotocin-induced diabetic neuropathy.4 It also prevents capillary strand formation in a rat model of diabetes-induced retinal microangiopathy when administered at a dose of 50 mg/kg.5

1.Terashima, H., Hama, K., Yamamoto, R., et al.Effects of a new aldose reductase inhibitor on various tissues in vitroJ. Pharmacol. Exp. Ther.229(1)226-230(1984) 2.Yasunari, K., Kohno, M., Kano, H., et al.Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucoseHypertension35(5)1092-1098(2000) 3.Yasunari, K., Kohno, M., Kano, H., et al.Aldose reductase inhibitor prevents hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucoseArterioscler. Thromb. Vasc. Biol.15(12)2207-2212(1995) 4.Kikkawa, R., Hatanaka, I., Yasuda, H., et al.Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic ratsDiabetologia24(4)290-292(1983) 5.Kojima, K., Matsubara, H., Mizuno, K., et al.Experimentally induced diabetic retinal microangiopathy and polyol pathway. II. Effect of aldose reductase inhibitors on microangiopathyNippon Ganka Gakkai Zasshi89(2)247-256(1985)

产品文档 Product Documents

Purity:>99.00%Appearance:A solid

化学性质Chemical Properties

CAS 号
N/A
SMILES
CC(/C=C1SC(N(CC(O)=O)C\1=O)=S)=C\C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H]
分子式
C15H8D5NO3S2
分子量
324.4 g/mol
溶解性
DMSO: slightly soluble,Methanol: slightly soluble
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至 37°C,然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备 RT,或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol